[Skip to Navigation]
Sign In
Comment & Response
February 17, 2022

PSMA PET in Prostate Cancer—A Biomarker or a Surrogate End Point?—Reply

Author Affiliations
  • 1Department of Radiology and Biomedical Imaging, University of California, San Francisco
  • 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
  • 3Department of Radiology and Biomedical Imaging, San Francisco VA Medical Center, San Francisco, California
  • 4David Geffen School of Medicine, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles
  • 5Department of Nuclear Medicine, University of Duisburg-Essen, German Cancer Consortium (DKTK)–University Hospital Essen, Essen, Germany
JAMA Oncol. 2022;8(4):644-645. doi:10.1001/jamaoncol.2021.7994

In Reply We thank Bowling and Dimitrakoff for their insightful comments on our recent prospective phase 3 imaging trial1 demonstrating a sensitivity of prostate-specific membrane antigen (PSMA) 68Ga-PSMA-11 positron emission tomographic (PET) imaging for detection of pelvic nodal metastases at the time of initial staging of 0.40. We agree with the authors that future work using PSMA PET as a response marker will be valuable, and further work should be performed to build off of the PRIMARY trial2 to better understand how to use PSMA PET and multiparametric magnetic resonance imaging in initial diagnosis. Additionally, there clearly is a relationship between disease aggressiveness and PSMA expression in the primary tumors.3

Add or change institution